Benign Breast Diseases In Women: A Review

Adepu Usha Sree*, Appam. Harinandini, Avinassh Tippani, Shyam sunder
Balaji Institute of Pharmaceutical Sciences, Lakenepally, Narsampet, Warangal.

ABSTRACT
Benign breast diseases can occur any time during the life span of a female [1]. Breast is a dynamic organ which undergoes cyclical changes throughout a woman’s reproductive life. Hormones and growth factors acting on the epithelial and stromal elements right from the onset of puberty till menopause cause significant morphological changes leading to Aberration in Normal Development and Involution (ANDI) inflicting majority of benign breast illnesses. [2]

Keywords: Beningn breast diseases, Fibroadenoma, Fibroadenosis, Breast abscess.

*Corresponding Author Email: bhuvana.rockers@gmail.com
Received 14 April 2019, Accepted 03 May 2019
INTRODUCTION
The breasts are specialized organs, that are located on the anterior chest wall. The female breast is greater developed than the male breast, as their primary feature is to produce milk for vitamins of the little one and child. Female hormones inclusive of oestrogen and progesterone are essential in promoting growth and changes that arise inside the breast, especially for the duration of pregnancy and the menstrual cycle \[3\][4]

**Physiological Changes In Breast**
1) Changes during menstrual cycle
2) Changes during pregnancy
3) Changes during lactation
4) Changes at menopause

1) **Changes during Menstrual cycle**
Retention of fluid during luteal phase, breast engorgement and pain\[5-7\]

2) **Breast Changes During Pregnancy**
During pregnancy, many adjustments arise within the breast, to put together for the child and produce milk. Cells within the glands of breast tissue change shape and increase in size and number. Later in being pregnant, subsequent increases in breast size arise via cells which secrete milk products and those secretory products gathering within the ducts. A special thick white/yellow fluid known as colustrum is produced within the breast throughout the previous couple of weeks of being pregnant and first few episodes of nursing. This is rich in protein and agents which protect the infant from harmful substances together with microorganism. \[5-7\]

3) **Changes During Lactation**
The alveoli are distended with milk, the cells become cuboidal, there is resultant diminution of intralobular space\[5-7\]

4) **Changes At Menopause**
Menopause is when a woman has no longer menstrual periods. At this stage, the ovaries have stopped releasing eggs and generating most in their estrogen. Menopause is diagnosed when a female has gone without a period for 12 consecutive months

**BENIGN BREAST DISEASES**
The term “Benign breast diseases” includes a heterogeneous group of lesions and may present with wide range of symptoms \[8\]. Benign breast disease is a neglected entity despite the fact that it constitutes the majority of breast complaints \[9\]. The vast majority of the lesions that occur in the
breast are benign. Breast is a dynamic organ which undergoes cyclical changes throughout a woman’s reproductive life. Hormones and growth factors acting on the epithelial and stromal elements right from the onset of puberty till menopause cause significant morphological changes leading to Aberration in Normal Development and Involution (ANDI) causing majority of benign breast diseases.\textsuperscript{[2]} Benign breast diseases can occur any time during the life span of a female. The aberrations of normal development and involution (ANDI) classification of benign breast diseases provides an overall framework for benign conditions of the breast that encompasses both pathogenesis and the degree of abnormality \textsuperscript{[1]}. It is a bidirectional framework based on the fact that most benign breast diseases arise from normal physiologic processes. Most benign breast diseases can be regarded as minor aberrations of normality and hence do not demand specific treatment \textsuperscript{[1]}

CLASSIFICATION OF BENIGN BREAST DISEASES

1) Non proliferative breast lesions
   1a) simple breast cysts
   1b) papillary apocrine change

2) Proliferative breast lesions without atypia
   2a) Usual ductal hyperplasia
   2b) Intraductal papilloma
   2c) Sclerosing adenosis
   2d) Simple fibroadenomas

3) Atypical hyperplasia (Atypical ductal and lobular hyperplasia)

4) Flat epithelial atypia

5) Miscellaneous lesions of the breast
   5a) Lipoma
   5b) Fat necrosis
   5c) Giant fibroadenoma
   5d) Juvenile fibroadenoma
   5e) Complex fibroadenoma
   5f) Diabetic mastopathy
   5g) Galactocele
   5h) Idiopathic granulomatous mastitis (IGM)
   5i) Nipple discharge
   5j) Breast pain
1) NON PROLIFERATIVE BREAST LESIONS

Non proliferative breast lesions are generally they are not associated with an increased risk of breast cancer [10]. It should be noted the terms such as fibrocystic changes, chronic cystic mastitis and mammary dysplasia refer to non proliferative lesions and are not useful clinically.

1a) Simple Breast Cysts

Simple cysts are fluid filled, round, or ovoid masses derived from the terminal duct lobular unit. Breast cysts can present as breast masses or mammographic abnormalities. Cysts are common in women between 35 and 50 years old. [11]

1B) Papillary Apocrine Change

Papillary apocrine change is a proliferation of ductal epithelial cells showing apocrine features, characterized by eosinophilic cytoplasm. [11]

2) PROLIFERATIVE BREAST LESIONS WITHOUT ATYPIA

2a) Usual Ductal Hyperplasia

Ductal hyperplasia without atypia is a pathologic diagnosis, usually found as an incidental finding on biopsy of mammographic abnormalities or breast masses, characterized by an increased number of cells within the ductal space. Although the cells vary in size and shape, they retain the cytological features of benign cells. [11]

2b) Intraductal Papillomas

Intraductal papillomas consists of monotonous array of papillary cells that grow from the wall of a cyst into its lumen. Although they are not concerning in and of themselves, they can harbor areas of atypia or ductal carcinoma in situ. Papillomas can occur as solitary or multiple lesions.

2c) Sclerosing Adenosis

Sclerosing adenosis is a lobular lesion with increased fibrous tissue. It can present as a mass or a suspicious finding on mammogram. No treatment is needed for sclerosing adenosis. The risk of subsequent breast cancer in this population is small, and chemoprevention is not indicated. [12]

2d) Simple Fibroadenomas

These are benign solid tumors containing glandular as well as fibrous tissue. The etiology of fibroadenomas is not known, but a hormonal relationship is likely since they persist during the reproductive years, can increase in size during pregnancy or with estrogen therapy, and usually regress after menopause. They are most commonly found in women between the ages of 15 and 35 years. [13]

3) ATYPICAL HYPERPLASIA

It includes both atypical duct hyperplasia and atypical lobular hyperplasia.
3a) Atypical Ductal Hyperplasia
ADH is characterized by a proliferation of uniform epithelial cells with monomorphic round nuclei filling part, but not the entirety, of the involved duct.[11]

3b) Atypical Lobular Hyperplasia
ALH is characterized by monomorphic, evenly spaced, dyshesive cells filling part, but not all, of the involved lobule. Atypical lobular hyperplasia can also involve ducts.[11]

4) Flat Epithelial Atypia
Flat epithelial atypia is a separate entity from Atypical ductal hyperplasia (ADH), Atypical lobular hyperplasia (ALH). Flat epithelial atypia is sometimes referred to as columnar cell change with atypia or columnar cell hyperplasia with atypia.

5) MISCELLANEOUS LESIONS OF BREAST:

5a) Lipoma
Breast lipoma are benign, usually solitary tumors composed of mature fat cells. They present as soft, on tender masses.[14]

5b) Fat Necrosis
Fat necrosis of the breast is a benign condition that most commonly occurs as the result of breast trauma or surgical intervention.[14]

5c) Giant Fibroadenomas
Giant fibroadenomas refer to histologically typical fibroadenomas over 10cm in size. Excision is recommended.[11]

5d) Juvenile Fibroadenomas
It occurs in young women between the ages of 10 and 18 years.

5e) Complex Fibroadenomas
They present as a mass on physical examination or a nodule on mammogram or ultrasound. They are associated with a slightly increased risk of cancer when multi-centric proliferative changes are present in the surrounding glandular tissue.[15]

5f) Diabetic Mastopathy
Diabetic mastopathy also known as lymphocytic mastitis seen in postmenopausal women who have long standing type 1 diabetes mellitus. Core biopsy is recommended for diagnostic confirmation.[16]

5g) Galactoceles
Galactoceles are cystic collection of fluid, usually caused by an obstructed milk duct. Diagnosis can be made based on the clinical history and aspiration, which yields a milky substance.[17]
5h) Idiopathic Granulomatous Mastitis
IGM is an inflammatory mass in the breast. The symptoms are breast abscess, nonpuerperal mastitis. biopsy is necessary to make a diagnosis.

5i) Nipple discharge
Discharge is considered pathologic if it is spontaneous, persistent or arises from a single duct. it is also pathologic if the discharge contains gross blood.

5j) Breast Pain
Breast pain is classified as cyclical, noncyclical. breast cancer may present as breast pain.

RISK FACTORS FOR BENIGN BREAST DISEASES

Clinical Examination of a Patient with Benign Breast Disease.

1. Characterize symptoms
2. Identify risk factors for breast cancer
3. Age
4. At menarche
5. At first live birth
6. Number of relatives with breast cancer
7. Age at diagnosis
8. Number of previous breast biopsies
9. Presence of atypical hyperplasia or lobular carcinoma in situ on previous breast biopsy
10. If patient is postmenopausal
11. Age at menopause, Duration of use of estrogen or progestin therapy

Physical examination
- Palpate the four breast quadrants while patient is sitting and lying down
- Identify discrete lumps and examine for regional nodes, Determine whether consistency is doughy with vague nodularity findings consistent with fibrocystic changes
- Determine whether discharge is viscous, watery, serosanguineous, grossly bloody, clear, blue–black, or green and Determine whether occult blood is present
- Examine lateral chest wall while patient is lying on her side (at 90 degrees), to move breast away from chest wall

**MANAGEMENT OF BENIGN BREAST DISEASES**

A detailed history and physical examination are used to evaluate systematically the entire breast and the chest wall and should focus on areas related to the patient’s symptoms. The “triple test” of breast lumps. Mammography, often conjunction with ultrasonographic examination, is required for evaluation of discrete palpable lesions in women more than 35 years of age; ultrasonography provides an optional substitute among younger women. Round dense lesions detected on mammography often are cysts that require ultrasonographic examination to distinguish them from solid lesions. For solid lesions, core needle biopsy (histologic analysis) directed with the use of radiographic provides highly discriminative information with regard to the presence or absence of malignant disease. Fine-needle aspiration suitable for cytologic evaluation.

The roles of magnetic resonance imaging (MRI) and digital mammography in the evaluation of breast lesions are currently being investigated. Galactography is useful in the detection of focal lesions within a single duct.

In the treatment of all patients with benign breast disease, clinical judgment is required to provide the proper balance between the intense and frequent surveillance needed for some patients and the risk of over diagnosis and treatment for others.

**Treatment:**

**Cyclic breast pain**

The most important issue in the management of cyclic breast pain is to decide whether to treat. In the absence of a mass or discharge, moderate signs warrant reassuring the patient regarding the absence of serious or severe disease. Precise fitting of a brassiere to provide support for pendulous breasts may provide pain relief. Lowering the dose of estrogens in the treatment of postmenopausal women or the addition of an androgen to estrogen-replacement therapy appears to be beneficial in reducing breast pain. The use of oral contraceptives has not been systematically studied. No standard regimen for moderate-to-severe breast pain has been widely accepted. Initial recommendations may include the use of mild analgesic agents such as acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDs), or aspirin. [23],[24],[20] Even evening primrose oil has been used, at oral doses of 1 to 3 g daily, on the basis of two randomized studies, [25] but recent trials question its efficacy. [26]

**Non cyclic breast pain**

When pain is truly arising from the breast, the approach outlined for cyclic pain used. In two thirds of women with diffuse chest-wall pain, the condition responds to oral or topical non steroidal anti inflammatory drugs. [27]

**Focal lesions**

Careful examination distinguishes between solitary, discrete, dominant, persistent masses and vague nodularity and thickening. The examination should be repeated at mid cycle after one or two menstrual cycles. If the abnormality resolves, the patient should be reassured, and if it does not, the patient should be referred to a surgeon. Breast imaging may be appropriate. Women older than 35 years of age with a dominant mass should undergo diagnostic mammography [19] and should then be referred to a surgeon. Postmenopausal women are referred for surgical consultation after undergoing mammography. For gross cysts, fine-needle aspiration with imaging studies repeated within six months. Non bloody fluid is discarded, but if the same cyst refills, surgical consultation is warranted. If bloody, the fluid should be sent for cytologic analysis and consultation with a surgeon should be requested.

Usual practice requires the triple test (palpation; mammography, often in conjunction with ultrasonography; and biopsy) for women more than 35 years of age with dominant masses.

**Nipple discharge**

It divides into two categories according to the presence or absence of galactorrhea. The presence of a discharge in association with a palpable mass and positive results on mammography warrants evaluation of the mass. Galactorrhea is considered pathologic if spontaneous. A workup for galactorrhea includes measurement of prolactin and thyrotropin levels and appropriate endocrinologic evaluation and treatment if the levels are elevated. [28] If the levels of both are normal, treatment with dopaminergic agonists may be initiated if the patient desires to reduce the fluid leak. A discharge in the absence of galactorrhea is considered to be ductal in origin and is classified as either uniductal or multiductal. [28] When the discharge is from one duct, and particularly if it is grossly bloody or the results of testing for occult blood are positive, a further workup is needed. Galactography with the use of cannulation and insertion of dye into the single duct emitting blood at the nipple allows visualization of a space-occupying lesion.
REFERENCES

1. Hughes LE, Mansel RE, Webster DJTW: Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders, Lancet 1987;2:1316.

2. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275-85

3. Ross MH, Gordon GI, Pawlina W. Breast anatomy Histology 2003

4. Moore KL, Dalley AF. Clinically Orientated Anatomy. Canada: Lippincott Williams & Wilkins; 1999.

5. Hussain MT. Comparison of FNAC with excision biopsy of breast lump. J Coll physicians Surg pak2005;15(4):211-4

6. Homesh NA, Issa MA, EL-Sofiani HA. The diagnostic accuracy of FNAC versus core needle for palpable breast lump(s). Saudi Med J 2005;26(1):42-6.

7. Tiwari M. Role of fine needle aspiration cytology in diagnosis of breast lumps. Kath.uni Med J.2007;5(2):18:215-217

8. Mima B, Maychet Sangma, Kishori Panda, Simon Dasiah. A clinico-pathological study on benign breast diseases. J clinical and Diagnostic Res 2013 Mar;7(3):503-506

9. Srivatsava A, Dhar A. Benign breast disease: A neglected entity. Recent Advances in surgery.2006;10:175-201.

10. Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003;27:836

11. Schnitt, SJ, Collins, LC. Pathology of benign breast disorders. In: breast diseases, Harris, JR, et al, Lippincott, 2010

12. Wang J, Costantino JP, Tan –chiu E, et al. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer 2004;96:616

13. Carty NJ, Carter C, Rubin C, et al. Management of fibroadenoma of the breast. Ann R Coll Surg Engl 1995;77:127

14. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis and management 2006;11:435

15. Sklair-levy M, Sella T, Alweiss T, et al. Incidence and management of complex fibroadenomas 2008;190:214

16. Lai EC, Chan WC, Ma TK, et al. The role of Conservative treatment in idiopathic granulomatous mastitis. Breast j 2005;11:454
17. Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics 2007:27
18. Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? JAMA 1999;282:1270-80.
19. Shetty MK, Shah YP, Sharman RS. Prospective evaluation of the value of combined mammographic and sonographic assessment in patients with palpable abnormalities of the breast. J Ultrasound Med 2003;22: 263-8.
20. Groves AM, Carr M, Wadhera V, Lennard TWJ. An audit of cytology in the evaluation of nipple discharge: a retrospective study of 10 years’ experience. Breast 1996;5: 96-9.
21. Gateley CA, Miers M, Mansel RE, Hughes LE. Drug treatments for mastalgia: 17 years experience in the Cardiff Mastalgia Clinic. J R Soc Med 1992;85:12-5.
22. Wilson MC, Sellwood RA. Therapeutic value of a supporting brassiere in mastodynia. Br Med J 1976;2:90.
23. Goodwin PJ, Neelam M, Boyd NF. Cyclical mastopathy: a critical review of therapy. Br J Surg 1988;75:837-44.
24. Santen R, Pinkerton J. Benign breast disorders. In: DeGroot LJ, Jameson JL, Burger H, et al., eds. Endocrinology. Philadelphia: W.B. Saunders, 2002:2189-98.
25. Pashby NL, Mansel RE, Hughes LE, Hanslip JI, Preece P. A clinical trial of evening primrose oil in mastalgia. Br J Surg 1981;68:801-24.
26. Goyal A, Mansel RE, Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with or without antioxidants, vitamins and minerals in the management of mastalgia. Breast J 2005;11: 41-7.
27. Kollias J, Sibbering DM, Blamey RW. Topical non-steroidal anti-inflammatory gel for diffuse chest wall pain in mastalgia patients. In: Mansel RE, ed. Recent developments in the study of benign breast disease. London: Parthenon Publishing, 1997:119-24
28. Falkenberry SS. Nipple discharge. Obstet Gynecol Clin North Am 2002;29:21-9.